CLINICAL PRACTICE GUIDELINES
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship
NCCN GUIDELINES®|Learn More

Clinical Evidence

Extensive clinical evidence shows that using ImpediMed’s bioimpedance spectroscopy (BIS) technology for early detection and intervention reduces the impact of chronic lymphedema on breast cancer patients.

It is Well Established that Breast Cancer Related Lymphedema (BCRL) can be Resolved with Early Detection and Intervention

Opportunity for Prevention is Before Noticeable Swelling Occurs

Lymphedema develops in stages, and a university of Kansas study found that when lymphedema is detected at stage 0 or stage 1 it is reversible, but in stages 2 and 3 it is not. These findings demonstrate how early conservative intervention and prospective monitoring with BIS can significantly lower rates of BCRL and persistent BCRL (pBCRL).¹

It is Well Established that Breast Cancer Related Lymphedema (BCRL) can be Resolved with Early Detection and Intervention

ImpediMed’s BIS Technology is Most Effective Method for Early Lymphedema Detection

The PREVENT Trial involved 10 centers across the US and Australia and was the largest randomized controlled trial (RCT) to assess lymphedema prevention in breast cancer patients.

Learn More About PREVENT

Triggers and Interventions

ImpediMed’s BIS technology is more precise and reliable than tape measure in detecting lymphedema (LE), as there are statistically significantly fewer triggers and interventions for those assessed with BIS compared to tape measure (p=0.011)2.

Progression to Chronic Lymphedema

Additionally, with early detection using BIS technology and intervention there is significantly lower progression to chronic lymphedema compared to using tape measure (p=0.016), which is the primary endpoint result2.

RESOURCES

Review the Strong Literature Included in our Clinical Evidence Summaries for Lymphedema Prevention Program.

RESOURCES

Read More About L-Dex in our Clinical Evidence Summaries.

RESOURCES

Discover PREVENT, the Largest Randomized Trial to Assess Lymphedema Prevention!

All
Guidelines
Lymphedema prevention
L-Dex detection limit
Validation studies
Economics quality of life
Filter

HEART FAILURE

Monitoring of body fluid in patients with chronic heart failure using Bioimpedance-Spectroscopy

Beckmann, L., et al.

BIS offers a good possibility to monitor the water content of a person. This can be used in monitoring decompensated CHF patients. Since most patients with acute heart failure suffer not only from lung edema, but also from edema in limbs a combination of segmental and whole body BIS measurements offers the best options to supervise the course of diseases. In this paper, both BIS measurements show a strong correlation with the water balance and weight loss.

Open access: No
View

References

  1. Kilgore L, at al. Reducing breast cancer-related lymphedema (BCRL) through prospective surveillance monitoring using bioimpedance spectroscopy (BIS) and patient direction self-interventions. Ann Surg Oncol 2018;http://doi.org/10.1245/s10434-018-6601-8.
  2. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022.